Skip Navigation

This Article
Right arrow Print PDF (5512K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Shterman, N.
Right arrow Articles by Kaufmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shterman, N.
Right arrow Articles by Kaufmann, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1995, Vol. 23, No. 10 1744-1749
© 1995

MOLECULAR BIOLOGY

Cleavage of the HIV replication primer tRNALys,3 in human cells expressing bacterial anticodon nuclease

Nava Shterman+,, Orna Elroy-Stein1, llan Morad, Michal Amitsur and Gabriel Kaufmann*,

Department of Biochemistry Tel Aviv 69978, Israel 1Department of Cell Research and Immunology, Tel Aviv University Tel Aviv 69978, Israel

* To whom correspondence should be addressed

Received January 27, 1995. Revised March 30, 1995. Accepted March 30, 1995.

Anticodon nuclease is a bacterial restriction enzyme directed against tRNALv8. We report that anticodon nuclease also cleaves mammalian tRNALys molecules, with preference and site specificity shown towards the natural substrate. Expression of the anticodon nuclease core polypeptide PrrC In HeLa cells from a recomblnant vaccinia virus elicited cleavage of intra-cellular tRNALys,3The data justify an inquiry into the possible application of anticodon nuclease as an inhibitor of tRNALys,3-primed HIV replication. They also indicate that the anticodon region of tRNALys is a substrate recognition site and suggest that PrrC harbors the enzymatic activity.

+Present address: Research and Development Department, Teva Pharmaceuticals Industries, PO Box 353, Kfar Sava 44102, Israel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
D. Klaiman, M. Amitsur, S. Blanga-Kanfi, M. Chai, D. R. Davis, and G. Kaufmann
Parallel dimerization of a PrrC-anticodon nuclease region implicated in tRNALys recognition
Nucleic Acids Res., July 9, 2007; 35(14): 4704 - 4714.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. Blanga-Kanfi, M. Amitsur, A. Azem, and G. Kaufmann
PrrC-anticodon nuclease: functional organization of a prototypical bacterial restriction RNase
Nucleic Acids Res., June 21, 2006; 34(11): 3209 - 3219.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Jiang, S. Blanga, M. Amitsur, R. Meidler, E. Krivosheyev, M. Sundaram, A. C. Bajji, D. R. Davis, and G. Kaufmann
Structural Features of tRNALys Favored by Anticodon Nuclease as Inferred from Reactivities of Anticodon Stem and Loop Substrate Analogs
J. Biol. Chem., February 1, 2002; 277(6): 3836 - 3841.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
X. Wei, M. Gotte, and M. A. Wainberg
Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers
Nucleic Acids Res., August 15, 2000; 28(16): 3065 - 3074.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.